Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488228 | 1.00 | MAPT (0.63) | MAPTTDP1ALDH1A1POLBMEN1 | |
| SCHEMBL7490971 | 1.00 | MAPT (0.63) | MAPTTDP1ALDH1A1POLBMEN1 | |
| SCHEMBL7493115 | 1.00 | MAPT (0.63) | MAPTTDP1ALDH1A1POLBMEN1 | |
| SCHEMBL7500985 | 0.90 | TDP1 (0.64) | MAPTTDP1ALDH1A1POLBMEN1 | |
| SCHEMBL7501001 | 0.90 | TDP1 (0.64) | MAPTTDP1ALDH1A1POLBMEN1 | |
| SCHEMBL7490272 | 0.90 | L3MBTL1 (0.70) | MAPTTDP1ALDH1A1POLBMEN1 | |
| SCHEMBL7494293 | 0.90 | MAPT (0.60) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL7494297 | 0.90 | MAPT (0.60) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL7490274 | 0.90 | L3MBTL1 (0.70) | MAPTTDP1ALDH1A1POLBMEN1 | |
| SCHEMBL7501258 | 0.89 | MAPT (0.72) | MAPTALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022125776-A2 | METHODS AND COMPOSITIONS FOR TREATING KIDNEY DISEASES | SIWA CORPORATION (US) | 2022-06-16 | — | — | WO | claimed |
| US-20100152125-A1 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases | BRANDEIS UNIVERSITY (US) | 2010-06-17 | — | — | US | claimed |
| EP-2139460-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES | Brandeis University (US) | 2010-01-06 | — | — | EP | claimed |
| EP-2124934-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | Beiersdorf AG (DE) | 2009-12-02 | — | — | EP | claimed |
| EP-2117536-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | Beiersdorf AG (DE) | 2009-11-18 | — | — | EP | claimed |
| WO-2008116092-A1 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES | BRANDEIS UNIVERSITY (US) | 2008-09-25 | — | — | WO | claimed |
| WO-2008101692-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | BEIERSDORF AG (DE) | 2008-08-28 | — | — | WO | claimed |
| WO-2008101693-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | BEIERSDORF AG (DE) | 2008-08-28 | — | — | WO | claimed |
| US-7297689-B2 | Method for preparing peritoneal dialysate | Kurokawa, Kiyoshi (JP) | 2007-11-20 | — | — | US | claimed |
| US-20050267045-A1 | Method for preparing peritoneal dialysate | TOSHIO MIYATA | 2005-12-01 | — | — | US | claimed |
| US-6919326-B1 | Carbonyl-stress improving agent and peritoneal dialysate | Miyata, Toshio (JP) | 2005-07-19 | — | — | US | claimed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | claimed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | claimed |
| CN-1037842-C | Substituted thiazolidine derivatives, pharmaceutical compositions and uses thereof | OTSUKA PHARMA CO LTD (JP) | 1998-03-25 | — | — | CN | claimed |
| CN-1106982-A | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1995-08-16 | — | — | CN | claimed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | claimed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | claimed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152125-A1 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases | SOD1, SOD3, AGER | MAPT 197/4885TDP1 433/4885ALDH1A1 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.